Literature DB >> 3034792

Incidence of bilateral testicular germ cell cancer in Denmark, 1960-84: preliminary findings.

A Osterlind, J G Berthelsen, N Abildgaard, S O Hansen, H Jensen, B Johansen, J Munck-Hansen, L H Rasmussen.   

Abstract

The incidence of a second primary testicular germ cell cancer in the contralateral testicle among 2338 men with a first primary testicular germ cell cancer diagnosed in the years 1960-79 in Denmark was established in this preliminary report. The material represents 83% of the total cohort followed until 31 December 1984. The relative risk for a patient with testicular cancer to get yet another testicular cancer was studied, taking into account the histology of the first primary testicular germ cell cancer. Based on fifty-eight nonsimultaneous contralateral testicular cancer cases and 19,995 'person-years at risk', the overall relative risk of invasive germ cell cancer in the contralateral testicle following a first germ cell testicular cancer was found to be 23.3 (95% confidence interval: 18-30). Among men with nonseminoma the risk was higher (relative risk = 27.5) than among men with seminomas (relative risk = 20.1). Overall, sixty-two (2.7%) patients developed a second cancer. In four of these patients bilateral tumours occurred simultaneously.

Entities:  

Mesh:

Year:  1987        PMID: 3034792     DOI: 10.1111/j.1365-2605.1987.tb00185.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  3 in total

1.  Abnormal ultrasonic pattern in contralateral testes in patients with unilateral testicular cancer.

Authors:  S Lenz; N E Skakkebaek; N T Hertel
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

Review 2.  Testicular Germ Cell Tumours and Proprotein Convertases.

Authors:  Aitziber Velado-Eguskiza; Laura Gomez-Santos; Iker Badiola; Francisco José Sáez; Edurne Alonso
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

3.  Inheritance and testicular cancer.

Authors:  P W Nicholson; S J Harland
Journal:  Br J Cancer       Date:  1995-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.